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cu.2012.Abstract The solid dispersion method was originally used to improve the dissolution properties
and the bioavailability of poorly water soluble drugs by dispersing them into water soluble carriers.
In addition to the above, dissolution retardation through solid dispersion technique using water
insoluble and water swellable polymer for the development of controlled release dosage forms
has become a ﬁeld of interest in recent years. Development of controlled release solid dispersion
has a great advantage for bypassing the risk of a burst release of drug; since the structure of the
solid dispersion is monolithic where drug molecules homogeneously disperse. Despite the remark-
able potential and extensive research being conducted on controlled release solid dispersion system,
commercialization and large scale production are limited. The author expects that recent technolog-
ical advances may overcome the existing limitations and facilitate the commercial utilization of the
techniques for manufacture of controlled release solid dispersions. This article begins with an over-
view of the different carriers being used for the preparation of controlled release solid dispersion
and also different techniques being used for the purpose. Kinetics of drug release from these con-
trolled release solid dispersions and the relevant mathematical modeling have also been reviewed in
this manuscript.
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Many problems are associated with conventional multiple dos-
ing regimen of long acting therapy, such as systemic accumu-
lation of the drug leading to side effects or toxicities,
irregular proﬁle of the plasma drug level, and poor patient
compliance. Controlled release drug delivery systems have
the potential of solving these problems. Controlled release sys-
tems are the methods that can achieve therapeutically effective
concentration of drug in the systemic circulation over an ex-
tended period of time with better patient compliance. Various
approaches ranging from coated tablets and gels to biodegrad-
able microparticles and osmotic systems have been used in an
attempt to sustain the drug release from dosage forms. In most
of the controlled release formulations, immediately upon
placement in the release medium, an initial large bolus of drug
is released before the release rate reaches a stable proﬁle. This
phenomenon is typically referred to as ‘burst release’. Burst re-
lease leads to higher initial drug delivery and also reduces the
effective life time of the device. For controlling drug release,
the solid dispersion method is an alternative approach. Solid
dispersion methods have been used widely in various formula-
tions to increase dissolution rate and bioavailability of poorly
water-soluble drugs.1–7 Solid dispersion in general releases the
drug immediately to maximize the absorption. Preparation of
matrices with water insoluble and water swellable polymers
using solid dispersion technique is a valuable method in the
production of controlled release products. Many studies have
been reported in the literature for the preparation of controlled
release system using solid dispersion technique.8–14 The con-
trolled release solid dispersions are generally prepared by any
of the methods: by dissolving the ingredients in a solvent fol-
lowed by drying, or by melting the active and inert ingredients
together followed by solidiﬁcation, or a combination of the
two methods. In solid dispersion, the dissolution of active
ingredient is affected by the presence of other components,in particular the carriers. These carriers include ethyl cellulose,
hydroxypropyl cellulose, hydroxypropyl methylcellulose, cellu-
lose acetate phthalate, ethyl acetate, chitosan, and methacrylic
acid copolymers. The structure of the solid dispersion is mono-
lithic wherein the drug molecules homogeneously disperse and
it has a great advantage of avoiding the risk of burst release
concerning the reservoir type controlled release preparations.
Despite an active research interest, there is no commercial
application of controlled release solid dispersion in dosage
form design. Improvement of solubility and bioavailability of
poorly water soluble drugs using solid dispersion technique
has been reviewed by many authors.15–22 However, until now
there are no reports in the literature on review of controlled
drug delivery system using solid dispersion technique. This
article provides an overview of current research on controlled
release drug delivery system using solid dispersion technique.
2. Carriers used in controlled release solid dispersions
Water insoluble carriers are generally used to produce con-
trolled release solid dispersion. The properties of the carriers
have the major inﬂuence on the release proﬁle of the dispersed
drug. Fig. 1 shows the chemical structure of some carriers used
for the preparation of controlled release solid dispersion.
2.1. Ethyl cellulose [EC]
Ethyl cellulose, an ethyl ether of cellulose, is a long chain poly-
mer of b-anhydroglucose units joined together by acetal link-
ages. It is a hydrophobic polymer and is used extensively as
a coating material for the preparation of microcapsules, micro-
spheres and tablets, a binder for the preparation of conven-
tional as well as matrix type controlled release tablets, etc. It
is also used in solid dispersion for water soluble drugs, or spar-
ingly water soluble drugs. Various concentrations of EC have
been used for the preparation of dimenhydrinate controlled
Figure 1 Structural formulae of some controlled release solid dispersion forming carriers.
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Differential scanning colorimetry [DSC] and X-ray diffraction
[X-RD] studies indicated that the drug is dispersed amor-
phously in the EC matrix. Infrared spectroscopy [IR] study re-
vealed that there was no chemical interaction of the drug with
EC, even in the amorphous state when the granules were pre-
pared by the solid dispersion method. There was no signiﬁcant
change in the crystalline properties of the drug in the granules
after exposure to 40% and 68% RH. However, on exposure to
100% RH, the granules with 1:1 drug: EC content showed the
formation of hydrates of the drug. It has been observed that
the amount of EC used for solid dispersion has a direct effect
on the release rate of the drug. For example, the drug release
reduced to about 26% with 1:5 drug-polymer ratio. Iqbal
et al.24 developed a controlled release tablet dosage form of na-
proxen by employing the conventional wet-granulation meth-
od and the solid dispersion method using EC as the rate
controlling polymer. Tablet prepared by wet granulation meth-
od containing 6% EC released 84% of the drug in 12 h, while
the formulation containing 28% EC the release rate dropped
to 30% in 12 h. Similarly, tablets prepared by solid dispersion
technique with 4% EC showed 88% of the drug released in
12 h, while the formulation containing 45% EC the release rate
dropped to 30% in 12 h. The in vitro release study indicated
that solid dispersion requires lower amounts of the polymer
[4%] than wet granulation [6%] to produce similar release
proﬁles. Table 1 presents some of the drugs used to prepare
controlled release solid dispersion using EC.
2.2. Hydroxypropyl cellulose [HPC]
HPC is manufactured by treatment of cellulose with sodium
hydroxide, followed by a reaction with propylene oxide at an
elevated temperature and pressure. It is commercially availablein a number of grades having different solution viscosities with
molecular weight ranging from 46,000 to 12,46,000. HPC is
primarily used in tableting as a binder, ﬁlm-coating and ex-
tended release matrix former. It is also used in microencapsu-
lation process and as a thickening agent. Ozeki et al.31
prepared controlled release solid dispersion granules of oxep-
renolol hydrochloride by solvent evaporation method using
EC and four grades of HPC having different molecular
weights. The release rate of oxeprenolol hydrochloride de-
creased with an increasing amount of HPC and becomes al-
most constant at the composition ratio of 3% and more. The
bulk viscosity is related to the molecular weight of HPC and
a markedly larger bulk viscosity was observed with a higher
molecular weight of HPC. However, there was little noticeable
change in release rate and activation energy for the diffusion of
oxeprenolol hydrochloride from solid dispersion. In another
study, Yuasa et al.32 investigated the effect of interaction be-
tween ﬂurbiprofen and HPC on the release of drug from con-
trolled release solid dispersion. The X-RD pattern and DSC
curves showed that ﬂurbiprofen exists in an amorphous state
in the solid dispersion. IR spectra conﬁrmed the hydrogen
bonding interaction between ﬂurbiprofen and HPC. It has also
been observed that the percent of ﬂurbiprofen forming a
hydrogen bond with HPC in the solid dispersion increased
with decreasing HPC molecular weight or with an increase in
the amount of HPC. Moreover a linear relationship was found
between the release rate of ﬂurbiprofen and the percent of the
hydrogen bonded ﬂurbiprofen in the solid dispersion.
2.3. Hydroxypropyl methylcellulose [HPMC]
HPMC is mixed alkyl hydroalkyl cellulose ether containing
methoxy and hydroxypropyl groups. It is prepared by reacting
alkali treated cellulose ﬁrst with methyl chloride to introduce
Table 1 Drugs used to prepare controlled release solid dispersion using EC.
Drug Method of preparation Release characteristics Reference
Diclofenac sodium Freeze drying Solid dispersions showed slower
drug dissolution than the pure
drug
25
Oxeprenolol hydrochloride Solvent evaporation The release rate of drug slightly
decreased with increasing
molecular weight of EC
26
Indomethacin Solvent evaporation Hydrophobic interaction between
indomethacin and EC occurred
under lower pH region and
strongly delayed dissolution of
indomethacin
27
Nifedipine Phase-separation Retardation of drug release 28
Ketoprofen Spray drying Prolonged release of drug 29
Acetaminophen Solvent evaporation Drug release decreased as the
amount of EC increased in the
solid dispersion
30
Dimenhydrinate Solvent evaporation Increase in the amount of EC
decreases the drug release rate
23
Naproxen Solvent evaporation Developed formulation showed
controlled release of naproxen with
a release proﬁle greater than 12 h
24
150 T.K. Giri et al.methoxy groups and then with propylene oxide to introduce
propylene glycol ether groups. USP speciﬁed four different
types of HPMC according to their degree of methoxy and
hydroxypropoxy substitution. These are HPMC 1828, HPMC
2208, HPMC 2906 and HPMC 2910. The ﬁrst two numbers
indicate the percentage of hydroxypropoxy groups, determined
after drying at 105 C for 2 h. Swain et al.33 prepared sustained
release solid dispersions of verapamil hydrochloride by solvent
evaporation method using polymers like HPMC K4M, Eudra-
git RSPO and their mixture. FT-IR spectra conﬁrmed the ab-
sence of interaction between drug and polymer. In vitro release
study showed that the drug release has been extended up to
16 h with solid dispersions containing HPMC; whereas solid
dispersion containing Eudragit showed extension up to 10 h
and solid dispersion containing both the polymers extended
the release up to 12 h respectively. They suggested that HPMC
acts as a better release retardant for the model drug. Tanaka
et al.34 investigated in vivo absorption of nilvadipine in dogs
by orally administering disintegration controlled matrix tablet
[DCMT] containing solid dispersion granules of the drug. The
solid dispersion granules were prepared by dissolving HPMC
in a mixture of ethanol and dichloromethane, followed by dis-
persing L-HPC and/or lactose into the solution. Then the sol-
vent was evaporated by a vacuum dryer at 40 C. In vivo study
showed improved solubility and sustained absorption of the
drug.
2.4. Hydroxypropyl methylcellulose phthalate [HPMCP]
HPMCP is cellulose in which some of the hydroxyl groups are
replaced by methyl ether, 2-hydroxypropyl ether and phthalyl
esters. Various types of HPMC are commercially available
with molecular weight ranging from 20,000 to 2,00,000. It is
widely used in oral tablet or granule formulations as an enteric
coating material. It is insoluble in gastric ﬂuid but will swell
and dissolve in the upper intestine. Sustained release solid dis-
persed composite particles were prepared with HPMCP andchitosan, as a carrier using a spray drying method.35 FT-IR
spectroscopy study conﬁrmed the hydrogen bond interaction
between the carbonyl group of HPMCP with the amino group
of acetaminophen. Spray dried pharmaceutical preparation
containing drug, chitosan and HPMCP at their weight ratio
of 1:2.5:2.5 delayed the drug release by about 30 times more
than that prepared by spray drying method. Similarly, alben-
dazole loaded solid dispersion was prepared using HPMCP
as a polymer by solvent evaporation method.36
2.5. Eudragit
Polyacrylates and polymethacrylates, the glassy substances, are
commonly referred to by the trade name Eudragit. Several
types of Eudragit are commercially available and may be ob-
tained as a dry powder, or as an aqueous dispersion, or as an
organic solution. The commonly used Eudragits for the prepa-
ration of controlled release solid dispersions are Eudragit L,
Eudragit RL, Eudragit RS, Eudragit RLPO and Eudragit
RSPO. Eudragit L is an anionic copolymerization product of
methacrylic acid and methylmethacrylate and is readily soluble
in neutral to weakly alkaline water. Eudragit RL and Eudragit
RS, are ammonio methacrylate copolymers. Eudragit RL con-
tains 10% of functional quaternary ammonium groups and
Eudragit RS possesses 5% of functional quaternary ammo-
nium groups. The ammonium groups are present as salts and
are mainly responsible for pH independent permeability of
the polymers. The Eudragit RL types are highly permeable
compared to the Eudragit RS types. Duarte et al.37 carried
out extensive studies on the inﬂuence of polymer combinations
such as Eudragit RL and Eudragit RS on the release proﬁle of
drug. Formulation containing excess of Eudragit RS caused a
slower release of drug than that containing higher amount of
Eudragit RL. Moreover, the drug release is controlled by diffu-
sion mechanism and the derived kinetic constant increases with
the increase in the content of Eudragit RL in the polymer blend.
In another study, sustained release systems of metoprolol
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RLPO and Eudragit RSPO by melting – solvent method.38
The drug release from solid dispersion was at a slower rate than
from pure drug and from physical mixture. The solid dispersion
containing greater amount of Eudragit RSPO showed slower
release rates than that containing greater amount of Eudragit
RLPO. The release rate of various drugs can be controlled with
Eudragit including Nimodipine,39 Verapamil hydrochloride,40
Nifedipine,28 Albendazole.36
2.6. Polyvinylpyrrolidone-co-vinyl acetate 62 [PVP-VA62]
PVP-VA62 is a copolymer of vinylpyrrolidone and vinylace-
tate in a ratio of 6:4, manufactured by a free radical polymer-
ization in isopropanol. It is soluble both in extremely
hydrophilic liquids such as water and in hydrophobic solvents
such as butanol. This polymer is also freely soluble in methy-
lene chloride, chloroform, ethanol, isopropanol and propylene
glycol. Verreck et al.41 prepared solid dispersion of itraconaz-
ole and PVP-VA62 by hot stage extrusion method. Release of
the drug from the solid dispersion was found to be inﬂuenced
by processing temperature and pressure.
2.7. Other carriers
Many other substances have been tested as carrier for con-
trolled release solid dispersion.
Terminalia catappa Linn is a tree belongs to the family
Combretaceae, largely distributed in tropical and subtropical
beaches. The leaves, trunk bark and fruits of the tree have been
used as a folk medicine in India. The gum exudates obtained
from T. catappa Linn are a natural release retarding polymer.
The gum exudates obtained from T. catappa Linn were re-
ported to sustain the release of dextromethorphan hydrobro-
mide by more than 8 h.42 The release kinetics showed that
the drug release mechanism involved in the matrix is anoma-
lous transport. Ozeki et al.43 attempted to control the drug re-
lease from solid dispersion composed of the polyethylene oxide
and carbopol interpolymer complex by varying the carbopol
grade. A small release rate was observed with low cross-linked
carbopol and middle cross-linked carbopol. Other materials
tested for controlled release solid dispersion include pluronic
F-66,44 compritol 888 ATO,45 poloxamer 188,9 methyl cellu-
lose,45 perbutanoyl-b-cyclodextrin,9 chitosan,25 kollidon
SR40 and ethyl vinyl acetate.39
3. Methods for preparing controlled release solid dispersion
3.1. Solvent evaporation method
The solvent evaporation method aims to dissolve the drug and
carrier simultaneously in a common solvent, followed by the
removal of solvent by evaporation. Identiﬁcation of a common
solvent for both drug and carrier can be problematic and com-
plete solvent removal from the product can be a lengthy pro-
cess. The solvent can be removed by various processes
including vacuum drying, heating of the mixture, slow evapo-
ration of the solvent at low temperature, the rotary evapora-
tors, spray drying and freeze drying. Many polymers and
drugs that could not be utilized for the melting method due
to their high melting points could be used for solvent evapora-
tion method. Controlled release solid dispersion of oxprenololhydrochloride was prepared by solvent evaporation method.48
The drug and polymer were dissolved in ethanol at 46 C fol-
lowed by evaporation to make the solid dispersion. The parti-
cle sizes of the granules and the drug–polymer ratio have been
found to govern the dissolution rate of the drug. Similarly
Yuasa et al.49 prepared sustained release solid dispersion gran-
ules of oxprenolol hydrochloride using solvent evaporation
method by dissolving or suspending drug in an organic sol-
vent. It has been observed that in a solid dispersion granule
composed of 25% oxprenolol hydrochloride, 68% EC and
5% HPC showed the sustained release behavior of drug.
Moreover, various dissolution behaviors could be obtained
by changing the particle size and the ratio of drug–polymer
in the granules. Oxprenolol hydrochloride loaded solid disper-
sion was also prepared using solvent evaporation method by
Ozeki et al.50 They prepared the solid dispersion by dissolving
the drug and polymers at various ratios in ethanol, and the sol-
vent was then evaporated. It was observed that the release rate
of oxprenolol hydrochloride reached a minimum level when
the content of HPC in the granules was within a range from
5% to 10%. Controlled release solid dispersion of various
drugs prepared by the solvent evaporation method is presented
in Table 2.
3.2. Melting method
The melting method involves melting of a physical mixture of
drug and carrier to the liquid state followed by cooling until
solidiﬁcation. However, the method is not suitable for thermo-
labile drugs and incomplete miscibility is observed between the
solid drug and molten carrier. Tran et al.52 prepared nano-
emulsifying Gelucire 28/14 based solid dispersion utilizing
melting method for controlled release of aceclofenac. They
investigated the dissolution modulating mechanism of alkali-
nizer [Na2CO3 and NaHCO3] and polymers [poloxamer 407]
for controlled release of drug. Solid dispersion containing alk-
alizers enhanced the initial release rate of the drug in simulated
gastric ﬂuid with precipitation, that was prevented by using
poloxamer 407 in the formulation. In another study, Nifedi-
pine tablets were prepared from solid dispersed granules pre-
pared by melting method using PEG4000 as the carrier
material.53 The solubility of nifedipine is too low in aqueous
medium. They incorporated the nifedipine as a solid dispersion
with PEG 4000 to increase dissolution rate and bioavailability
of drug. Carbopol was used as the coating material on both
sides of the central matrix containing solid dispersion to pro-
vide gel layer which may act as the rate controlling membrane.
The DSC thermogram and X-RD pattern indicated the ab-
sence of crystalline domain of Nifedipine in solid dispersion.
It was observed that the increase in pH, ionic strength and buf-
fer concentration of the dissolution medium decreases the re-
lease rate of drug. Rodrigues et al.54 developed a novel
polymeric matrix tablet containing a drug central core for co-
lonic delivery. The central core was formed by a solid disper-
sion of the drug into the polymer PEG4000 by melting
method and compared with that produced using lactose. Less
than 30% of the drug was released after 24 h from tablets with
lactose central core, whereas almost complete drug release was
found from tablet having PEG4000 central core. Moreover, by
controlling the temperature of molten PEG4000 solution and
the solid dispersion viscosity, the spherical core size can be
properly controlled. The solid dispersion tablets were prepared
Table 2 Preparation of controlled release solid dispersion of drugs by solvent evaporation method.
Drug Carrier (s) Solvent Solvent removal Dosage form Remark Reference
Nifedipine HPMC, HPC, Lactose Dichloromethane, ethanol Slow evaporation at ambient
condition
Tablet The release of drug was sustained
without any recrystallization
51
Indomethacin EC, HPMC Ethanol Evaporation under reduced
pressure using rotary
evaporator at 30 C
– Hydrophobic interaction
between drug and EC occurred at
lower pH and strongly delayed
the dissolution rate of drug
27
Flurbiprofen HPC Ethanol Slow evaporation at ambient
condition
Granules The release rate of drug increased
with decreasing HPC molecular
weight
32
Oxprenolol
hydrochloride
EC, HPC Ethanol Slow evaporation at ambient
condition
Films The release rate of drug
decreased with increasing HPC
concentration and becomes
almost constant at the HPC
concentration of 3% and more
31
Dimenhydrinate EC Ethanol Continuous heating on a hot
plate
Granules Crystalline drug was converted
into amorphous form in all the
solid dispersions
23
Verapamil
hydrochloride
HPMC, Eudragit RSPO Methanol Evaporated to dryness in a
desiccator under vacuum
– HPMC acts as a better release
retardant for the model drug
33
Albendazole HPMC, HPMCP Ethanol, Dichloromethane Evaporation at 43 C in a
jacketed beaker connected to
a thermostated water bath
– Elution proﬁle and predicted
absorption were extremely pH-
dependent
36
Dextromethorphan
hydrobromide
Terminalia catappa Linn Ethanol Evaporation at reduced
pressure at 56 C with
constant stirring
Tablet Release sustained up to more
than 8 h
42
Nimodipine Ethyl vinyl acetate, Eudragit
RL100, Ethyl acetate
Acetone Evaporation in a desiccator
under vacuum
Tablet In comparison to pure drug the
release has been extended
39
Nifedipine Pluronic F-66 Mixture of acetone, alcohol and water Spray drying Pellets Increase of drug-polymer ratio is
proportional to extend of release
44
Phenacetin Methyl cellulose, carbopol Mixture of water and ethanol Evaporation with an
evaporator at 46 C
– Release rate depends on the
complexation between the
polymers
46
Verapamil
hydrochloride
Eudragit RLPO, Kollidon SR Acetone The solvent was removed
under vacuum using rotary
evaporator within 46 C
Tablet Eudragit is found better than the
Kollidon SR in controlling the
drug release
40
Phenacetin Polyethylene oxide, carbopol Mixture water and ethanol Evaporation at 46 C – Polyethylene oxide-carbopol
complex controlled the release
rate. Degree of crosslinking
between the polymers depends on
carbopol grade
43
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888ATO as a carrier by melting method. Matrix tablet pre-
pared by using physical mixture released the drug completely
within 12 h, while from the tablets prepared with solid dis-
persed granules the release was found extended for over
24 h. Similarly, controlled release solid dispersion was pre-
pared by melting method using losartan potassium9 and
metoprolol.38
3.3. Melting solvent method
The melting solvent method is a combination of the two meth-
ods solvent evaporation and melting method. It is performed
by dissolving the drug in a suitable solvent and mixing of this
solution with the molten carrier followed by cooling for solid-
iﬁcation. The advantage of this method is that it requires lower
temperatures with lesser risk of decomposition of thermolabile
drugs. Chen et al.55 developed a new concept to combine the
solid dispersion technique and osmotic pump technique for
water insoluble drug, 10-hydroxycamptothecin to improve sol-
ubility with controlled release of drug. The solid dispersion of
drug was prepared by the melting solvent method using PEG
as the carrier and methanol as the solvent. The optimum for-
mulation was able to deliver drug at a constant rate of
1.21 mg/h for up to 12 h in simulated intestinal ﬂuid, and
cumulative release at 12 h was above 90%.
3.4. Spray drying
Spray drying is the process where a solution of drug substance
and carrier is evaporated by spraying the solution as ﬁne drop-
lets into a chamber under controlled conditions of heat,
humidity and air ﬂow. The drying medium is typically air
and the product is then separated after completion of drying.
Composite particles of acetaminophen with chitosan and
HPMCP were prepared by solid dispersion technique using a
4-ﬂuid nozzle spray dryer.35 Scanning electron micrographs
study showed that the spray drying of pharmaceutical prepara-
tion can achieve spherical particles with mean particle size of
0.54–13.46 lm. X-ray diffraction and DSC measurement re-
sults suggested that acetaminophen and the carriers could
not form solid dispersion with simple physical mixing. How-
ever spray drying of drug and carriers at certain ratio [acetami-
nophen: chitosan: HPMCP = 1:2.5:2.5] produced solid
dispersion of desired characteristics. The ratio of drug to car-
rier inﬂuenced the degree of crystallinity in the solid disper-
sions. Similarly, 4 ﬂuid-nozzle spray-drying technique was
used for the preparation of controlled release solid dispersion
of acetaminophen using chitosan as a carrier.56 The X-RD
study revealed that the drug was amorphous in solid disper-
sion. Furthermore, the FT-IR spectra conﬁrmed the hydrogen
bonding between the carboxyl group of acetaminophen and
amino group of chitosan. The resultant formulation containing
drug to polymer ratio 1:5 showed sustained release proﬁle in
all pH test solutions. Kamada et al.29 prepared repeat and pro-
longed release solid dispersion of ketoprofen-HP-b-CD com-
plex and of ketoprofen-EC using spray drying method. They
investigated in vitro and in vivo release behavior of this system
using rats. It has been observed that the co-administration of
the complex and EC solid dispersion gave a constant plasma
Ketoprofen level for at least 24 h. In another study, composite
solid dispersion particles of salbutamol sulfate were preparedby a 4-ﬂuid nozzle spray drying technique using Eudragit RS
or Eudragit RL as a carrier.57 X-RD patterns revealed that
the drug was amorphous and formed a solid dispersion.
3.5. Hot melt extrusion
Hot melt extrusion [HME] is a widely used process in plastic,
rubber, and food industry. The process has been useful in the
preparation of solid dispersion in a single step. Initially HME
is used to prepare solid dispersion to enhance solubility of
poorly water soluble drugs. Subsequently, its value in develop-
ing controlled release preparation has gained more attraction.
The advantages of hot-melt extrusion include lower tempera-
ture and shorter residence time of the drug carrier mixture.
Typically, physical mixture of drug substance and other ingre-
dient is fed into the heated barrel of extruder at a controlled
rate. As the physical mixture is conveyed through heated
screws, it is transformed into a ﬂuid like state, which allows
intimate and homogeneous mixing by the high shear of extru-
der screws (Figs. 2 and 3). The die then shapes the melt in the
required form such as granules, pellets, tablets, sheets, sticks or
powder.
Ozawa et al.58 prepared solid dispersions of water insoluble
drug (ethenzamide) and water soluble drug (theophylline) by
twin screw extruder method. Solid dispersions obtained by
using the twin screw extruder show signiﬁcantly increased eth-
enzamide release, but the release rate of theophylline de-
creased. Theophylline dissolved more rapidly when used
alone but when it is used in solid dispersion with carbopol
the solubility is reduced and also delayed the drug release
due to the interaction between the –N–H of theophylline and
–COOH of carbopol. While the rapid dissolution of ethenza-
mide is observed in the solid dispersion since ethenzamide
was completely dispersed which enhances the wettability of
drug. The effect of plasticizer level on drug release was inves-
tigated from sustained release dosage forms prepared by hot-
melt extrusion and ﬁlm coating using either Eudragit RSPO
or Eudragit RD100 as the polymer and triethyl citrate (TEC)
as the plasticizer.59 It was observed that the release rates of
both diltiazem hydrochloride and chlorpheneramine maleate
increased from hot-melt extrudates with an increase in the
TEC level in the formulations. However, the release rate of dil-
tiazem from the Eudragit RS30D-coated pellets decreased with
an increase in TEC in the coating dispersion.
3.6. Supercritical antisolvent method
In recent years, processing of pharmaceuticals with supercriti-
cal ﬂuids has received increased attention. The supercritical
ﬂuid exists as a single ﬂuid phase above its critical temperature
and critical pressure. Carbon dioxide is the most commonly
used supercritical ﬂuid. Depending on the method by which
solution and supercritical ﬂuid are introduced and mixed into
each other, different terminology have been used by different
researchers: (a) precipitations from supercritical solutions by
rapid expansion of supercritical solution,60 (b) precipitation
from saturated solution using supercritical ﬂuid as an antisol-
vent,61 (c) precipitation from gas saturated solutions.62,63
Supercritical antisolvent related to various processes may be
aerosol solvent extraction system (ASES),64,65 solution en-
hanced dispersion by supercritical ﬂuids (SEDS),66,67 gas anti-
solvent (GAS),68 and supercritical antisolvent (SAS).69
Figure 2 Stages of hot melt extrusion process.
Figure 3 Schematic diagram of hot melt extrusion.
154 T.K. Giri et al.Schematic diagram of the supercritical antisolvent apparatus is
shown in Fig. 4.
In GAS or SAS process a mixture of drug and polymer is
sprayed through an atomizer into a chamber ﬁlled with super-
critical ﬂuids. The expansion and extraction of organic solvent
into the compressed gas result in lowering the solvent power of
organic solvent for drug and polymer leading to precipitation.
Duarte et al.37 prepared acetazolamide composite microparti-
cles by supercritical anti-solvent technique using Eudragit
RS100 and RL100 as carriers for ophthalmic drug delivery.
The composite particles in the size range of 8–40 lm were pro-
duced by semi-continuous process and batch process. Particles
prepared by the batch process had a mean diameter larger than
that produced by semi-continuous process. Composite parti-
cles containing Eudragit RS led to a slower release of drug
than those containing Eudragit RL. Moreover, particles
prepared by batch process exhibited faster release than those
prepared by the semi-continuous process.
3.7. Other methods
Huang et al.70 prepared matrix type microparticles containing
solid dispersion of nifedipine with polymers by phase separa-
tion method for controlled drug delivery. It was observed that
the microparticles’ size, morphology, and size distribution
were not affected by drug loading. At lower levels of drug
loading, nifedipine release was well described by the Beker
and Lonsdale‘s matrix diffusion model. However, at higher
levels of drug loading a change in the release kinetics was ob-
served. Dangprasirt and Pongwai25 prepared diclofenac so-
dium loaded controlled release solid dispersion powders and
capsules by freeze-drying technique using EC and chitosan as
carriers. In vitro release study indicated that the ratio of EC
and chitosan was an important factor in controlling the disso-
lution of the solid dispersion. Ikeda et al.47 prepared controlled
release solid dispersion of captopril by kneading method using
a combination of hydrophilic and hydrophobic cyclodextrin
derivatives. It has been observed that a combination of hydro-
philic and hydrophobic cyclodextrin was useful for controlling
the drug release.4. Mathematical modeling of drug release from controlled
release solid dispersion based systems
In order to establish the mathematical modeling of drug re-
lease, the experimental data are ﬁtted to different kinetic mod-
els. Various mathematical kinetic models like zero order, ﬁrst
order, Higuchi, Hixson-crowell, etc. tried to justify the mecha-
nism of drug release. The commonly used mathematical models
for evaluating the release kinetics of drug are shown in Table 3.
Higuchi developed several theoretical models to describe
the release rate of water soluble and poorly soluble drugs from
matrix system. Initially, it was valid only for planar systems.
However, later it has been modiﬁed and extended to different
geometrics and matrix systems including porous structures.
Various researchers have used the Higuchi model to interpret
their experimental drug release from solid dispersion system.
Ozeki et al.50 investigated the effect of the composition ratios
between polymer and drug (oxprenolol hydrochloride) on the
release mechanism by using Higuchi and Baker–Lonsdale
model. The formulation, containing not more than 20% of
drug, released for a longer period of time and obeyed the Hig-
uchi and Baker–Lonsdale model. However, at 30% or more of
drug, the release rate did not obey the above mentioned model.
Korsmeyer developed semi-empirical equation to describe
drug release from polymeric system
Mt
Ma
¼ ktn
where k is a constant incorporating structural and geometric
characteristic of the system, Mt/Ma is the fraction release of
drug at time t, and n is the release exponent, indicative of
the drug release mechanism. Peppas characterized different re-
lease mechanisms by using this n value. The above equation
can be applied in two situations: [a] where n= 0.5 indicating
diffusion-controlled drug release [b] n= 1.0 indicating swell-
ing controlled drug release. Moreover, the values of n between
0.5 and 1 can be regarded as an indicator for the superposition
of both phenomena [anomalous transport]. The diffusional
exponent is dependent on the geometry of the device as well
as the release mechanism of drug [Table 4].71–73
Figure 4 Schematic diagram of the supercritical antisolvent
apparatus.
Table 4 Drug release mechanisms and diffusion exponent for poly
Release exponent [n]
Thin ﬁlm Cylinder
0.5 0.44
0.5 < n< 1.0 0.44 < n< 0.89
1.0 0.89
Table 3 Commonly used mathematical model for evaluating the re
S.N. Mathematical model name Mathematical equation
1 Zero order Qt ¼ Q0  K0t
2 First-order logQt ¼ logQ0  K1t2:303
3 Higuchi Qt ¼ KHt
4 Hixson-crowell Q
1=3
0 Q1=3t ¼ KSt
5 Baker–Lonsdale
3
2
½1 ð1 Mt
Ma
Þ2=3
 Mt
Ma
¼ 3DmCms
r20C0
t
6 Korsmeyer–peppas MtMa ¼ atn
7 Hopfenberg MtMa ¼ 1 ½1
K0
C0a0
n
8 Poiseuille’s law of laminar ﬂow dMdt ¼ pc8 r
4
g
P1P2
h
9 Weibull
log½ lnð1mÞ ¼ b logðt T
 log a
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scribe drug release from controlled release methylcellulose-
carboxyvinylpolymer interpolymer complex solid dispersion.
It was observed that the solid dispersion containing the
lowest molecular weight of methylcellulose showed n value
of approximately 1. As the molecular weight of methylcellulose
increased the n value decreased with improved drug release. In
another study, Korsmeyer–Peppas model was applied to gain
information about the release mechanism of drug from the so-
lid dispersion systems having various molecular weights of
ethyl cellulose. In case of drug and ethyl cellulose binary sys-
tem molecular weight of ethyl cellulose did not inﬂuence the
n value, it was found to be about 0.4. However, in a ternary
system containing drug, ethyl cellulose and hydroxypropyl cel-
lulose the n value increased with increasing molecular weight
of ethyl cellulose and reached 0.5. The results indicated thatmeric controlled delivery systems of different geometries.
Drug transport mechanism
Sphere
0.42 Fickian diﬀusion
0.42 < n< 0.85 Anomalous transport
0.85 Case-II transport
lease kinetics of drug.
Terms used in equation
Qt = amount of drug remaining as a solid state at time t;
Q0 = initial amount of drug in the pharmaceutical dosage
form; K0 = zero-order release rate constant
Qt = amount of drug remaining as a solid state at time t;
Q0 = initial amount of drug in the pharmaceutical dosage
form; K1 = First-order release rate constant
Qt = amount of drug released in time t; KH = Higuchi’s
release rate constant
Qt = amount of drug remaining as a solid state at time t;
Q0 = initial amount of drug in the pharmaceutical dosage
form; Ks =Release rate constant
Mt = amount of drug released at time t; Ma = amount of
drug released at an initial time; Dm = diﬀusion coeﬃcient;
Cms = drug solubility in the matrix; r0 = radius of the
spherical matrix; C0 = initial concentration of drug in the
matrix
Mt/Ma = fraction of drug released at time t; a= kinetic
constant; n= diﬀusional release exponent
Mt/Ma = fraction of drug dissolved; K0 = erosion rate
constant; C0 = initial concentration of drug in the matrix;
a0 = initial radius for matrix; n= 1, 2 and 3 for a slab,
cylinder and sphere, respectively.
dM/dt = drug release rate; c= concentration of drug in
matrix; r= radius of oriﬁce; g= viscosity of matrix; P1–
P2 = pressure diﬀerence between the inside and outside of the
membrane.
iÞ
m= fraction of the drug in solution at time t; a= time scale
of the process; b= shape parameter; Ti = lag time
Table 5 Release kinetics of various drugs from controlled release solid dispersion system.
Drug Polymer(s) Dosage form Kinetics model Observation References
Nilvadipine HPMC, HPC Tablet Hixon-crowell The release of drug is disintegration limited 51
Dimenhydrinate Ethylcellulose Granules First order Good ﬁt to ﬁrst order kinetics. The linearity of the drug
release is proportional to the content of ethylcellulose
following zero-order kinetic
23
Captopril Cyclodextrins Solid complex Korsmeyer–Peppas Initial drug release follows dissolution mechanisms,
subsequent drug release is controlled by a diﬀusion
mechanism.
47
Sodium diclofenac PEG 400, Eudragit RS 100 Tablet Korsmeyer–Peppas The release exponent values of all the formulations are
greater than one.
54
Nifedipine PEG 400 Tablet Korsmeyer–Peppas Diﬀerent formulations showing diﬀerent n values from
0.33–0.55.
53
Indomethacin EC, HPMC Solid dispersion Higuchi Release of indomethacin followed diﬀusional mechanisms
whose dissolution rate constants are pH depended.
27
Oxprenolol hydrochloride EC, HPC Solid dispersion ﬁlms Fick’s second law The resistance to diﬀusion of drug from the swollen HPC
gel of the solid dispersion was almost the same regardless
of the molecular weight of HPC.
31
10-hydroxy camptothecin PEG 400 Tablet Poiseuille’s law of laminar ﬂow The tablet prepared from solid dispersion has great
potential in the controlled delivery of water insoluble
drugs
55
Metoprolol Eudragit RLPO, Eudragit RSPO Solid dispersed particle Zero-order, Higuchi The formulation containing greater ratios of Eudragit
RSPO showed slower release rates than that containing
greater ratios of Eudragit RLPO
38
Nifedipine Pluronic F-66 Pellets First-order Pellets of solid dispersion showed a 12 h release proﬁle
following ﬁrst-order kinetics.
74
Diclofenac sodium Ethylcellulose Capsule First-order The dissolution of the solid dispersion powder and
capsules was closer to a ﬁrst-order model than to a zero-
order or diﬀusion control model
25
Indomethacin Eudragit Granules Higuchi, First-order The release process is diﬀusion controlled and dependent
on the initial drug concentration
75
Phenylpropanolamine HCl ATO 888 Tablet Higuchi The drug release followed the diﬀusion controlled model 76
1
5
6
T
.K
.
G
iri
et
a
l.
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diffusion theory. Kumar et al.42 investigated the effect of
formulation variables on the resulting n value of a sparingly
soluble model drug, dextromethorphan hydrobromide. It has
been observed that release kinetics of the drug from the system
was found to be anomalous transport with n values between
0.44 and 0.89.
Baker and Lonsdale’s release model was used for data anal-
ysis of controlled release molecular dispersion of Eudragit and
ethylcellulose binary blends.28 According to this model the ef-
fect of the ratio of the Eudragit to ethylcellulose on the drug re-
lease rate was analyzed by using two major parameters-particle
size [1/r2] and diffusion coefﬁcient [D]. The matrix permeability
expressed in terms of the effective drug diffusion coefﬁcient was
increased by increasing the ratio of Eudragit to ethylcellulose.
Moreover, an increase in the ratio of Eudragit to ethyl cellulose
resulted an upward trend in release rate. Further analysis was
performed to examine the effect of D and 1/r2, and of only D
on drug release. The former was found more inﬂuencing. The
most commonly used mathematical models describing the
release kinetics of various drugs from controlled release solid
dispersion systems are shown in Table 5.5. Conclusion
Solid dispersion systems have been utilized during the past four
decades to increase dissolution rate and bioavailability of
poorly soluble drugs. In recent years in addition to dissolution
rate and bioavailability enhancement great attention has been
paid to use solid dispersion for the development of controlled
release dosage forms. The solid dispersions have tremendous
potential in the area of controlled release dosage form design
because of the wide availability of a variety of carriers those
are either poorly soluble or swellable in aqueous medium.
These carriers include ethyl cellulose, hydroxypropyl cellulose,
hydroxypropylmethyl cellulose, carbopol, Eudragit, etc. The
judicious application of insoluble polymer and/or water swella-
ble polymer can retard the release pattern of a drug to a desired
extent. It is considered that the water soluble polymer swells in
water and is trapped by the water insoluble polymer resulting in
retardation of drug release. Various methods successfully used
for the preparation of controlled release solid dispersion in the
lab scale have been reviewed in this article. However, scale-up
of solid dispersion technology from lab scale to industrial scale
is limited. The application of hot melt extrusion and supercrit-
ical ﬂuid technology for the production of controlled release
solid dispersion is particularly an important breakthrough for
scale-up of solid dispersion manufacture. The great advantage
of controlled release solid dispersion is its monolithic structure
that avoids the risk of burst release. The release of drug from
controlled release solid dispersion is dependent upon the molec-
ular weight and concentration of carriers, drug-polymer ratio
and crosslinking degree of polymer. Proper selection of carrier
and accurate mathematical modeling are also keys to control
the release proﬁle of drug. However, many parameters in the
current mathematical models are unknown and need to be iden-
tiﬁed in order to accurately predict drug release proﬁles. De-
spite several efforts many troubles and challenges still remain
unexplored in developing controlled release solid dispersion
systems. Even so, as the research advances, the solid dispersionwill be one of the exciting frontiers of controlled release drug
delivery systems.References
1. Linn M, Collonot EM, Djuric D, Hempel K, Fabian E, Kolter K,
et al. Soluplus as an effective absorption enhancer of poorly
soluble drugs in vitro and in vivo. Eur J Pharm Sci
2012;45(3):336–43.
2. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ.
Enhanced bioavailability of sirolimus via preparation of solid
dispersion nanoparticles using a supercritical antisolvent process.
Int J Nanomedicine 2011;6:2997–3009.
3. Chen Y, Shi Q, Chen Z, Zheng J, Xu H, Li J, et al. Preparation
and characterization of emulsiﬁed solid dispersions containing
docetaxel. Arch Pharm Res 2011;34(11):1909–17.
4. Yan YD, Sung JH, Kim KK, Kim DW, Kim JO, Lee BJ, et al.
Novel valsartan-loaded solid dispersion with enhanced bioavail-
ability and no crystalline changes. Int J Pharm 2012;422(1–2):
202–10.
5. Tung NT, Park CW, Oh TO, Kim JY, Ha JM, Park ES.
Formulation of solid dispersion of rebamipide evaluated in a rat
model for improved bioavailability and efﬁcacy. J Pharm Phar-
macol 2011;63(12):1539–47.
6. Wu JX, Yang M, Berg F, Pajander J, Rades T, Rantanen J.
Inﬂuence of solvent evaporation rate and formulation factors on
solid dispersion physical stability. Eur J Pharm Sci 2011;44(5):
610–20.
7. Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH,
Nuijen B. Pharmaceutical development and preliminary clinical
testing of an oral solid dispersion formulation of docetaxel
(ModraDoc001). Int J Pharm 2011;420(2):244–50.
8. Kovacic B, Vrecer F, Planinsek O. Design of a drug delivery
system with bimodal pH dependent release of a poorly soluble
drug. Pharmazie 2011;66(6):465–6.
9. Tran HTT, Park JB, Hong KH, Choi HG, Han HK, Lee J, et al.
Preparation and characterization of pH-independent sustained
release tablet containing solid dispersion granules of a poorly
water soluble drug. Int J Pharm 2011;415(1–2):83–8.
10. Kanaujia P, Lau G, Ng WK, Widjaja E, Hanefeld A, Fischbach
M, et al. Nanoparticle formation and growth during in vitro
dissolution of ketoconazole solid dispersion. J Pharm Sci
2011;100(7):2876–85.
11. Patel MR, San Martin-Gonalez MF. Characterization of ergocal-
ciferol loaded solid lipid nanoparticles. J Food Sci 2012;77(1):
N8–N13.
12. Perge L, Robitzer M, Guillemot C, Devoisselle JM, Quignard F,
Legrand P. New solid lipid microparticles for controlled ibuprofen
release: formulation and characterization study. Int J Pharm
2012;422(1–2):59–67.
13. Kim HJ, Lee SH, Lim EA, Kim JS. Formulation optimization of
solid dispersion of mosapride hydrochloride. Arch Pharm Res
2011;34(9):1467–75.
14. Attama AA, Igbonekwu CN. In vitro properties of surface-
modiﬁed solid lipid microspheres containing an antimalarial drug:
halofantrine. Asian Pac J Trop Med 2011;4(4):253–8.
15. Bikiaris DN. Solid dispersions. Part I: recent evolutions and future
opportunities in manufacturing methods for dissolution rate
enhancement of poorly water-soluble drugs. Expert Opin Drug
Deliv 2011;8(11):1501–19.
16. Iqbal B, Ali A, Ali J, Baboota S, Dang S, Shadab M, et al. Recent
advances and patents in solid dispersion technology. Recent Pat
Drug Deliv Formul 2011;5(3):244–64.
17. Srinarong P, De WH, Frijlink HW, Hinrichs WL. Improved
dissolution behavior of lipophilic drugs by solid dispersions: the
158 T.K. Giri et al.production process as starting point for formulation consider-
ations. Expert Opin Drug Deliv 2011;8(9):1121–40.
18. Warren DB, Benameur H, Porter CJ, Pouton CW. Using
polymeric precipitation inhibitors to improve the absorption of
poorly water-soluble drugs: a mechanistic basis for utility. J Drug
Target 2010;18(10):704–31.
19. Tran PH, Tran TT, Lee KH, Kim DJ, Lee BJ. Dissolution-
modulating mechanism of pH modiﬁers in solid dispersion
containing weakly acidic or basic drugs with poor water solubility.
Expert Opin Drug Deliv 2010;7(5):647–61.
20. Qian F, Huang J, Hussain MA. Drug-polymer solubility and
miscibility: stability consideration and practical challenges in
amorphous solid dispersion development. J Pharm Sci
2010;99(7):2941–7.
21. Janssens S, Van den Mooter G. Review: physical chemistry of
solid dispersions. J Pharm Pharmacol 2009;61(12):1571–86.
22. Dhirendra K, Lewis S, Udupa N, Atin K. Solid dispersion: a
review. Pak J Pharm Sci 2009;22(2):234–46.
23. Desai J, Alexander K, Riga A. Characterization of polymeric
dispersions of dimenhydrinate in ethyl cellulose for controlled
release. Int J Pharm 2006;308:115–23.
24. Iqbal Z, Babar A, Ashraf M. Controlled-release naproxen using
micronized ethyl cellulose by wet-granulation and solid-dispersion
method. Drug Dev Ind Pharm 2002;28(2):129–34.
25. Dangprasirt P, Pongwai S. Development of diclofenac sodium
release solid dispersion powders and capsules by freeze drying
technique using ethylcellulose and chitosan as carriers. Drug Dev
Ind Pharm 1998;24(10):947–53.
26. Ozeki T, Yuasa H, Kanaya Y, Oishi K. Application of the solid
dispersion method to the controlled release of medicine. VII.
Release mechanism of a highly water-soluble medicine from solid
dispersion with different molecular weights of polymer. Chem
Pharm Bull 1995;43(4):660–5.
27. Ohara T, Kitamura S, Kitagawa T, Terada K. Dissolution
mechanism of poorly water-soluble drug from extended release
solid dispersion system with ethylcellulose and hydroxypropylm-
ethylcellulose. Int J Pharm 2005;302:95–102.
28. Huang J, Wigent RJ, Schwartz JB. Nifedipine molecular disper-
sion in microparticles of ammonio methacrylate copolymer and
ethylcellulose binary blends for controlled drug delivery: effect of
matrix composition. Drug Dev Ind Pharm 2006;32:1185–97.
29. Kamada M, Hirayama F, Udo K, Yano H, Arima H, Uekama K.
Cyclodextrin conjugate-based controlled release system: repeated
and prolonged-release of ketoprofen after oral administration in
rats. J Control Release 2002;82:407–16.
30. Ghaly ES, Hernandez JI, Malave A, Marti A. Ethylcellulose as a
carrier for controlled-release acetaminophen tablets. P R Health
Sci J 1992;11(3):159–62.
31. Ozeki T, Yuasa H, Kanaya Y, Oishi K. Application of the solid
dispersion method to the controlled release of medicine. VIII.
Medicine release and viscosity of the hydrogel of a water-soluble
polymer in a three-component solid dispersion system. Chem
Pharm Bull 1995;43(9):1574–9.
32. Yuasa H, Ozeki T, Takahashi H, Kanaya Y, Ueno M. Application
of the solid dispersion method to the controlled release of
medicine. VI. Release mechanism of a slightly water soluble
medicine and interaction between ﬂurbiprofen and hydroxypropyl
cellulose in solid dispersion. Chem Pharm Bull 1994;42(2):354–8.
33. Swain SK, Patra CN, Sruti J, Rao MEB. Design and evaluation of
sustained release solid dispersions of verapamil hydrochloride. Int
J Pharm Sci Nanotechnol 2011;3(4):1252–62.
34. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ibuki R,
et al. Development of novel sustained-release system, disintegra-
tion-controlled matrix tablet (DCMT) with solid dispersion
granules of nilvadipine (II): in vivo evaluation. J Control Release
2006;112:51–6.
35. Chen R, Takahashi H, Okamoto H, Danjo K. Particle design of
three-component system for sustained release using a 4-ﬂuidnozzle spray-drying technique. Chem Pharm Bull
2006;54(11):1486–90.
36. Sugawara M, Kadomura S, He X, Takekuma Y, Kohri N,
Miyazaki K. The use of an in vitro dissolution and absorption
system to evaluate oral absorption of two weak bases in pH-
independent controlled-release formulation. Eur J Pharm Sci
2005;26:1–8.
37. Duarte ANC, Roy C, Gonzalez AV, Duarte CMM, Paternault PS.
Preparation of acetazolamide composite microparticles
by supercritical anti-solvent techniques. Int J Pharm
2007;332:132–9.
38. Varshosaz J, Faghihian H, Rastgoo K. Preparation and charac-
terization of metoprolol controlled-release solid dispersions. Drug
Deliv 2006;13:295–302.
39. Rathinaraj BS, Rajeevr C, Choudhury PK, Gannesh SB, Shinde
GV. Studies on dissolution behaviour of sustained release solid
dispersions of nimodipine. Int J Pharm Sci Rev Res
2010;3(1):77–82.
40. Sahoo J, Murthy PN, Biswal S, Manik. Formulation of sustained-
release dosage form of verapamil hydrochloride by solid disper-
sion technique using Eudragit RLPO or Kollidon SR. AAPS
Pharm Sci Tech 2009;10(1):27–33.
41. Verreck G, Decorte A, Heymans K, Adriaensen J, Cleeren D,
Jacobs A, et al. The effect of pressurized carbon dioxide as a
temporary plasticizer and foaming agent on the hot stage
extrusion process and extrudate properties of solid dispersions of
itraconazole with PVP-VA 64. Eur J Pharm Sci 2005;26:
349–58.
42. Kumar SV, Sasmal D, Pal SC. Rheological characterization and
drug release studies of gum exudates of Terminalia catappa Linn.
AAPS Pharm Sci Tech 2008;9(3):885–90.
43. Ozeki T, Yuasa H, Kanaya Y. Controlled release from solid
dispersion composed of poly(ethylene oxide)-Carbopol inter-
polymer complex with various cross-linking degrees of Carbo-
pol. J Control Release 2000;63:287–95.
44. Ho HO, Chen CN, Sheu MT. Inﬂuence of pluronic F-68 on
dissolution and bioavailability characteristics of multiple-layer
pellets of nifedipine for controlled release delivery. J Control
Release 2000;68:433–40.
45. Li FQ, Hu JH, Deng JX, Su H, Xu S, Liu JY. In vitro controlled
release of sodium ferulate from compritol 888 ATO-based matrix
tablets. Int J Pharm 2006;324:152–7.
46. Ozeki T, Yuasa H, Okada H. Controlled release of drug via
methylcellulose-carboxyvinylpolymer interpolymer complex solid
dispersion. AAPS Pharm Sci Tech 2005;6(2):E231–6.
47. Ikeda Y, Kimura K, Hirayama F, Arima H, Uekama K.
Controlled release of a water-soluble drug, captopril, by a
combination of hydrophilic and hydrophobic cyclodextrin deriv-
atives. J Control Release 2000;66:271–80.
48. Yuasa H, Ozeki T, Kanaya Y, Oishi K. Application of the solid
dispersion method to controlled release of medicine. II. Sustained
release tablet using solid dispersion granule and the medicine
release mechanism. Chem Pharm Bull 1992;40(6):1592–6.
49. Yuasa H, Ozeki T, Kanaya Y, Oishi K, Oyake T. Application of
the solid dispersion method to controlled release of medicine. I.
Controlled release of water soluble medicine by using solid
dispersion. Chem Pharm Bull 1991;39(2):465–7.
50. Ozeki T, Yuasa H, Kanaya Y, Oishi K. Application of the solid
dispersion method to controlled release of medicine. V. Suppres-
sion mechanism of the medicine release rate in the three-compo-
nent solid dispersion system. Chem Pharm Bull 1994;42(2):
337–43.
51. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ohike A,
et al. Development of novel sustained-release system, disintegra-
tion-controlled matrix tablet (DCMT) with solid dispersion
granules of nilvadipine. J Control Release 2005;108:386–95.
52. Tran TTD, Tran PHL, Lee BJ. Dissolution-modulating mecha-
nism of alkalizers and polymers in a nanoemulsifying solid
A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique 159dispersion containing ionizable and poorly water-soluble drug.
Eur J Pharm Biopharm 2009;72:83–90.
53. Hong SI, Oh SY. Dissolution kinetics and physical characteriza-
tion of three-layered tablet with poly(ethylene oxide) core matrix
capped by carbopol. Int J Pharm 2008;356:121–9.
54. Rodriguez MLG, Maestrelli F, Mura P, Rabasco AM. In vitro
release of sodium diclofenac from a central core matrix tablet
aimed for colonic drug delivery. Eur J Pharm Sci 2003;20:125–31.
55. Chen H, Jiang G, Ding F. Monolithic osmotic tablet containing
solid dispersion of 10-hydroxycamptothecin. Drug Dev Ind Pharm
2009;35:131–7.
56. Chen R, Okamoto H, Danjo K. Particle design using a 4-ﬂuid-
nozzle spray-drying technique for sustained release of acetamino-
phen. Chem Pharm Bull 2006;54(7):948–53.
57. Chen R, Okamoto H, Danjo K. Preparation of functional
composite particles of salbutamol sulfate using a 4-ﬂuid nozzle
spray-drying technique. Chem Pharm Bull 2008;56(3):254–9.
58. Ozawa M, Hasegawa K, Yonezawa Y, Sunada H. Preparation of
solid dispersion for ethenzamide-carbopol and theophylline-car-
bopol systems using a twin screw extruder. Chem Pharm Bull
2002;50(6):802–7.
59. Zhu Y, Mehta KA, McGinity JW. Inﬂuence of plasticizer level on
the drug release from sustained release ﬁlm coated and hot-melt
extruded dosage forms. Pharm Dev Technol 2006;11(3):285–94.
60. Kakumanu VK, Bansal AK. Supercritical ﬂuid technology in
pharmaceutical research. CRIPS 2003;4:8–12.
61. Hanna M, York P. Method and apparatus for the formation of
particles. WO9501221 (1995).
62. Sencar-Bozic P, Srcic S, Knez Z, Kerc J. Improvement of
nifedipine dissolution characteristics using supercritical CO2. Int
J Pharm 1997;148:123–30.
63. Kerc J, Srcic S, Sencar-Bozic P. Micronization of drugs using
supercritical carbon dioxide. Int J Pharm 1999;182:33–9.
64. Jung J, Perrut M. Particle design using supercritical ﬂuids:
literature and patent survey. J Supercrit Fluid 2001;20:179–219.
65. Bleich J, Muller BW. Production of drug loaded microparticles by
the use of supercritical gases with the aerosol solvent extraction
system (ASES) process. J Microencapsul 1996;13:131–9.66. Juppo AM, Boiddier C, Khoo C. Evaluation of solid dispersion
particles prepared with SEDS. Int J Pharm 2003;250:385–401.
67. Palakodaty S, York P, Pritchard J. Supercritical ﬂuid processing
of materials from aqueous solutions: the application of SEDS to
lactose as a model substance. Pharm Res 1998;15:1835–43.
68. Randolph TW, Randolph AD, Mebes M, Yeung S. Sub-microm-
eter-sized biodegradable particles of poly(L-lactic acid) via the gas
antisolvent spray precipitation process. Biotechnol Prog
1993;9:429–35.
69. Elvassore N, Baggio M, Pallado P, Bertucco A. Production of
different morphologies of biocompatible polymeric materials by
supercritical CO2 antisolvent techniques. Biotechnol Bioeng
2001;73:449–57.
70. Huang J, Wigent RJ, Bentzley CM, Schwartz JB. Nifedipine solid
dispersion in microparticles of ammonio methacrylate copolymer
and ethylcellulose binary blend for controlled drug delivery effect
of drug loading on release kinetics. Int J Pharm 2006;319:44–54.
71. Ritger PL, Peppas NA. A simple equation for description of solute
release. I. Fickian and non-Fickian release from non-swellable
devices in the form of slabs, spheres, cylinders or discs. J Control
Release 1987;5:23–36.
72. Ritger PL, Peppas NA. A simple equation for description of solute
release. II. Fickian and anomalous release from swellable devices.
J Control Release 1987;5:37–42.
73. Siepmann J, Peppas NA. Modeling of drug release from delivery
systems based on hydroxypropyl methylcellulose (HPMC). Adv
Drug Deliv Reviews 2001;48:139–57.
74. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW, Shah
NH. Multi-unit controlled release systems of nifedipine and
nifedipine: pluronic F-68 solid dispersions: characterization of
release mechanisms. Drug Dev Ind Pharm 2002;28(3):275–85.
75. Khanfar MS, Salem MS, Najib NM, Pillai GK. Dissolution
behavior of sustained release formulations of indomethacin with
Eudragit RS. Acta Pharm Hung 1997;67(6):235–9.
76. Perez MA, Ghaly ES, Marti A. Sustained release phenylpropa-
nolamine hydrochloride from ATO 888 matrix. P R Health Sci J
1993;12(4):263–7.
